They should execute on their own guidance. It is what I am most interested in now. They are going to ruin this company with this attitude to the business. Look at their earlier presentations. In August 2022, they guided start of Tusp registrational trial in Sep 2023. In Sep 2022, it was Oct 2023. Now it is moved to some time in 2024. It looks like they have no idea about what is required to start it.
Recent APTOF News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 11:35:19 AM
- Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical • GlobeNewswire Inc. • 04/30/2026 11:30:00 AM
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 04/01/2026 08:14:53 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 09:29:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 09:23:27 PM
- Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights • GlobeNewswire Inc. • 03/31/2026 09:22:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 08:59:27 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 03/23/2026 09:15:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 09:02:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:30:11 AM
- Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 11:40:10 AM
- Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders • GlobeNewswire Inc. • 02/24/2026 12:00:00 PM
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 02/17/2026 11:13:46 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 02/17/2026 11:06:40 AM
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 02/09/2026 11:15:56 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 02/09/2026 11:06:31 AM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 01/15/2026 02:26:21 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 01/15/2026 02:23:33 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 10:16:17 PM
- Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC • GlobeNewswire Inc. • 12/19/2025 10:05:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2025 12:15:26 PM
- Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations • GlobeNewswire Inc. • 12/06/2025 01:00:00 PM
- Form PREM14A - Preliminary proxy statements relating to merger or acquisition • Edgar (US Regulatory) • 12/05/2025 09:08:55 PM
